I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Signature: Mause a.

Docket No.: MIY-P01-032

(PATENT)

## PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Wagner et al.

Application No.: 10/631364

Confirmation No.: 2195

Filed: July 31, 2003

Art Unit: 3764

For:

BIOABSORBABLE CASING FOR

Examiner: Not Yet Assigned

SURGICAL SLING ASSEMBLY

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each foreign and non-patent reference on the PTO/SB/08 is attached.

Applicant(s) have also become aware of the following documents, cited by the International Searching Authority in the International Search Report issued December 14, 2004, during the prosecution of international application no. PCT/US2004/023842, which corresponds to the above referenced application, and in accordance with 37 CFR 1.97(c) and (e)(1) or (b)(3), hereby submits these documents for the Examiner's consideration. These documents are cited

Application No.: 10/631364 Docket No.: MIY-P01-032

on the enclosed PTO Form SB/08, and copies of the foreign document cited thereon are enclosed as well

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. MIY-P01-032. A duplicate copy of this paper is enclosed.

Dated: March 9, 2005

Respectfully submitted,

Agnes S. Lee

Registration No.: 46,862 ROPES & GRAY LLP One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

MAR 1 1 2005

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

Complete If Known						
Application Number	10/631364					
Filing Date	July 31, 2003					
First Named Inventor	James Wagner					
Art Unit	3764					
Examiner Name	Not Yet Assigned					
Attorney Docket Number	MIY-P01-032					

		_	U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
	AA	US-2001/0000533-A1	04-26-2001	Kovac, S.R.	1 32.007 \$100.
	AB	US-2001/0023356-A1	09-20-2001	Raz et al.	
	AC	US-2002/00127270	09-12-2002	Li et al.	
	AD	US-2002/00127270	01-31-2002	Therin et al.	
	AE	US-2002/0013530-A1	06-27-2002	Cabak et al.	
	AF	US-2002/0099260-A1	07-25-2002	Suslian et al.	
	AG	US-2002/055200-A1	10-24-2002	Gellman	-
	AH	US-2003/0004580-A1	01-02-2003		
	AI	US-2003/0010929-A1	01-16-2003		
	AJ	US-2003/0010325-A1	01-30-2003		
	AK	US-2003/0028075	02-06-2003		
	AL	US-2003/0026075	02-00-2003		
	AM	US-2003/0030070-A1	03-06-2003		
	AN	US-2003/0045892-A1	04-03-2003		
<u> </u>	AO	US-2003/0100954-A1	05-29-2003	Schuldt-Hempe et al.	
	AP	US-2003/0100954-A1	06-19-2003	Ulmsten et al.	
	AQ	US-2003/0114600 US-2003/0130670-A1	07-10-2003		
	AR	US-2003/0171644	09-11-2003	Anderson et al.	
	AS	US-2003/0171044 US-2003/0176762-A1	09-18-2003		
	AT	US-2003/0176762-A1	09-18-2003	Anderson et al.	
	AU	US-2003/0191480-A1	10-09-2003	Ulmsten et al.	
	AV	US-2003/0191400-A1	11-13-2003	Anderson et al.	
	AW	US-2004/0243166	12-04-2002	Ethicon Gmbh	
	AX	US-2004/0249240	12-04-2002	Ethicon Gmbh	
	AY	US-2005/0010078	01-13-2005	Jamiolkowski	
	AZ	US-2005/0010076	01-03-2005	Johnson & Johnson	<u> </u>
	AA1	US-2005/0010300	02-03-2005		
	AB1	US-3,565,073	02-03-2003	Giesy, J.D.	
	AC1	US-3,704,712	11-28-1972	Giesy et al.	
	AD1	US-4,798,193	01-17-1989	Giesy et al.	
	AE1	US-4,824,435	04-25-1989	Giesy et al.	
	AF1	US-4,872,451	10-10-1989	Moore et al.	
	AG1	US-4,946,467	08-07-1990	Ohi et al.	
		US-4,946,468	08-07-1990	Li, L.K.	
	AH1 Al1	US-5,002,550	03-26-1991	Li, L.K.	-
	AJ1	US-5,064,435	11-12-1991	Porter, C. H.	
	AK1	US-5,064,435 US-5,078,730	01-07-1992	Li, L.K.	
	AL1	US-5,084,058	01-07-1992	Li, L.K.	
	AM1	US-5,087,263	02-11-1992	Li	
	AN1	US-5,112,344	05-12-1992	Petros	
	AO1	US-5,112,344 US-5,133,723	07-28-1992	Li et al.	
	AP1		10-06-1992		
	AQ1	US-5,152,749 US-5,163,946	11-17-1992	Li	
	AR1	US-5,207,679	05-04-1993	Li, L.K.	
	AS1	US-5,250,033	10-05-1993	Evans et al.	
	IVOI	00-0,200,000	10-00-1993	Date	<u> </u>

Examiner Date Signature Considered

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substi	Substitute for form 1449A/B/PTO  INFORMATION DIS STATEMENT BY A  (Use as many sheets as		Complete if Known		
				Application Number	10/631364
INF	FORMATIO	N DIS	SCLOSURE	Filing Date	July 31, 2003
ST	ATEMENT	BY A	PPLICANT	First Named Inventor	James Wagner
			_	Art Unit	3764
	(Use as many st	neets as	necessary)	Examiner Name	Not Yet Assigned
Sheet	2	of	4	Attorney Docket Number	MIY-P01-032

ΙΔΤ1	US-5,256,150	10-26-1002	Quiachon et al.		<u> </u>
		08-02-1994			
	US-5,334,185	08-16-1994			
	US-5,337,736				
	US-5,368,595	11-29-1994			<del> </del>
	US-5,383,904		Totakura et al.		
	US-5,395,349		Quiachon et al.		
	US-5,439,467		Benderev et al.		
	US-5,456,722		McLeod et al.		
	US-5,505,735	04-09-1996			
	US-5,540,703		Barker, Jr. et al.		
	US-5,544,664		Benderev et al.		
	US-5,582,188		Benderev et al.		
	US-5,611,515		Benderev et al.		
	US-5,620,012		Benderev et al.		
	US-5,637,112	06-10-1997			
	US-5,645,589	07-08-1997			
	US-5,683,418		Luscombe et al.		
	US-5,690,649	11-25-1997			
	US-5,702,215	11-30-1997			
AM2	US-5,742,943	04-28-1998			
AN2	US-5,749,884		Benderev et al.		
AO2	US-5,766,221	06-16-1998	Benderev et al.	_	
AP2	US-5,813,408	09-29-1998	Benderev et al.		
AQ2	US-5,836,314	11-17-1998	Benderev et al.		
AR2	US-5,836,315	11-17-1998	Benderev et al.		
AS2	US-5,840,011	11-24-1998	Landgrebe et al.		
AT2	US-5,842,478	12-01-1998	Benderev et al.	•	
AU2	US-5,860,993	01-19-1999	Thompson et al		
	US-5,899,906	05-04-1999	Schenk		
AW2	US-5,899,909	05-04-1999	Claren et al.		
AX2	US-5,934,283	08-10-1999	Willem et al.		
	US-5,935,122		Fourkas et al.		
	US-5,954,057	09-21-1999			
	US-5,997,541	12-07-1999			
	US-6,001,104		Benderev et al.		·-
	US-6,039,686	03-21-2000		* .	
	US-6,042,534		Gellman et al.		
	US-6,050,937		Benderev, T.V.		
	US-6,053,935		Brenneman et al.		
	US-6,056,688		Benderev et al.		
	US-6,077,216		Benderev et al.		
	US-6,096,041		Gellman et al.		
	US-6,099,547		Gellman et al.		
	US-6,200,330-B1	03-13-2001	Benderev et al.		
	US-6,245,082-B1	06-12-2001	Gellman et al.		<del>                                     </del>
	US-6,264,676-B1	06-24-2001	Gellman et al.		
	US-6,273,852-B1	08-14-2001	Lehe et al.		
			Trabucco		<del> </del>
	US-6,306,079-B1 US-6,322,492-B1	10-23-2001			<u> </u>
	US-0,322,492-B1	11-27-2001	Kovac, S.R.		
xaminer ignature				Date Considered	

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO Application Number 10/631364 INFORMATION DISCLOSURE July 31, 2003 Filing Date STATEMENT BY APPLICANT First Named Inventor James Wagner Art Unit 3764 (Use as many sheets as necessary) Not Yet Assigned Examiner Name 4 Attorney Docket Number MIY-P01-032 3 of Sheet

AG3 US-6,382,686-B1   12-11-2001   Kovac, S.R.					
AS3 US-6,406,423-B1 06-18-2002 Scetbon, V. AT3 US-6,423,080-B1 07-23-2002 Gellman et al. AU3 US-6,440,154-B2 08-27-2002 Gellman et al. AV3 US-6,478,727-B2 11-12-2002 Scetbon, V. AW3 US-6,491,703-B1 12-10-2002 Ulmsten, U.  AX3 US-6,494,887-B1 12-17-2002 Kaladelfos, G. AY3 US-6,500,194-B2 12-31-2002 Benderev et al. AZ3 US-6,502,578-B2 01-07-2003 Raz et al. AA4 US-6,530,943-B1 03-11-2003 Hoepffner et al. AB4 US-6,582,443 06-24-2003 Cabak et al. AC4 US-6,596,001 07-22-2003 Stormby et al. AD4 US-6,596,002 07-22-2003 Therin et al. AB4 US-6,599,235 07-29-2003 Kovac AF4 US-6,605,097-B1 08-12-2003 Lehe et al. AG4 US-6,612,977-B1 09-02-2003 Staskin et al. AB4 US-6,638,209-B2 10-28-2003 Landgrebe, S. AI4 US-6,638,211-B2 10-28-2003 Berger, Y. AJ4 US-6,638,211-B2 10-28-2003 Rocheleau et al. AK4 US-6,641,525-B2 11-04-2003 Rocheleau et al. AK4 US-6,648,921-B2 11-18-2003 Rocheleau et al. AK4 US-6,685,2450-B2 11-25-2003 Neisz et al. AK4 US-6,685,2450-B2 11-25-2003 Neisz et al. AK4 US-6,685,2450-B2 11-25-2003 Rocheleau et al. AK4 US-6,680,2807 10-12-2004 Anderson et al. AK4 US-6,680,2807 10-12-2004 Anderson et al. AK4 US-6,802,807 10-12-2004 Carter et al.		AQ3	US-6,328,686-B1	12-11-2001	Kovac, S.R.
AT3 US-6,423,080-B1 07-23-2002 Gellman et al.  AU3 US-6,440,154-B2 08-27-2002 Gellman et al.  AV3 US-6,478,727-B2 11-12-2002 Scetbon, V.  AW3 US-6,491,703-B1 12-10-2002 Ulmsten, U.  AX3 US-6,594,94,887-B1 12-17-2002 Kaladelfos, G.  AY3 US-6,500,194-B2 12-31-2002 Benderev et al.  AZ3 US-6,502,578-B2 01-07-2003 Raz et al.  AA4 US-6,530,943-B1 03-11-2003 Hoepffner et al.  AB4 US-6,582,443 06-24-2003 Cabak et al.  AC4 US-6,596,001 07-22-2003 Stormby et al.  AD4 US-6,596,002 07-22-2003 Therin et al.  AE4 US-6,599,235 07-29-2003 Kovac  AF4 US-6,605,097-B1 08-12-2003 Lehe et al.  AG4 US-6,638,209-B2 10-28-2003 Landgrebe, S.  AI4 US-6,638,210-B2 10-28-2003 Suslian et al.  AK4 US-6,638,211-B2 10-28-2003 Suslian et al.  AK4 US-6,638,211-B2 10-28-2003 Rocheleau et al.  AK4 US-6,641,525-B2 11-04-2003 Rocheleau et al.  AK4 US-6,665,629-B2 11-25-2003 Reisz et al.  AK4 US-6,685,629-B2 11-25-2003 Reisz et al.  AK4 US-6,685,629-B2 11-25-2003 Rocheleau et al.  AK4 US-6,685,629-B2 11-25-2003 Rocheleau et al.  AK4 US-6,685,629-B2 11-25-2003 Reisz et al.  AK4 US-6,685,629-B2 11-25-2004 Anderson et al.  AK4 US-6,685,629-B2 11-25-2004 Anderson et al.  AK4 US-6,685,802,807 10-12-2004 Anderson et al.  AK4 US-6,802,807 10-12-2004 Anderson et al.		AR3	US-6,382,214-B1	05-07-2002	Raz et al.
AU3 US-6,440,154-B2 08-27-2002 Gellman et al.  AV3 US-6,478,727-B2 11-12-2002 Scetbon, V.  AW3 US-6,491,703-B1 12-10-2002 Ulmsten, U.  AX3 US-6,494,887-B1 12-17-2002 Benderev et al.  AX3 US-6,500,194-B2 12-31-2002 Benderev et al.  AZ3 US-6,502,578-B2 01-07-2003 Raz et al.  AA4 US-6,530,943-B1 03-11-2003 Hoepffner et al.  AB4 US-6,582,443 06-24-2003 Cabak et al.  AC4 US-6,596,002 07-22-2003 Stormby et al.  AD4 US-6,596,002 07-22-2003 Therin et al.  AE4 US-6,599,235 07-29-2003 Kovac  AF4 US-6,605,097-B1 08-12-2003 Lehe et al.  AG4 US-6,638,209-B2 10-28-2003 Landgrebe, S.  AI4 US-6,638,211-B2 10-28-2003 Berger, Y.  AJ4 US-6,634,525-B2 11-04-2003 Rocheleau et al.  AK4 US-6,644,525-B2 11-18-2003 Rocheleau et al.  AK4 US-6,648,921-B2 11-18-2003 Rocheleau et al.  AM4 US-6,658,629-B2 02-03-2004 Therin, M.  AO4 US-6,755,781 06-29-2004 Gellman  AP4 US-6,802,807 10-12-2004 Carter et al.	/	AS3	US-6,406,423-B1	06-18-2002	Scetbon, V.
AV3 US-6,478,727-B2 11-12-2002 Scetbon, V.  AW3 US-6,491,703-B1 12-10-2002 Ulmsten, U.  AX3 US-6,494,887-B1 12-17-2002 Kaladelfos, G.  AY3 US-6,500,194-B2 12-31-2002 Benderev et al.  AZ3 US-6,502,578-B2 01-07-2003 Raz et al.  AA4 US-6,530,943-B1 03-11-2003 Hoepffner et al.  AB4 US-6,582,443 06-24-2003 Cabak et al.  AC4 US-6,596,001 07-22-2003 Stormby et al.  AD4 US-6,596,002 07-22-2003 Therin et al.  AE4 US-6,599,235 07-29-2003 Kovac  AF4 US-6,605,097-B1 08-12-2003 Lehe et al.  AG4 US-6,612,977-B1 09-02-2003 Staskin et al.  AH4 US-6,638,209-B2 10-28-2003 Landgrebe, S.  AI4 US-6,638,210-B2 10-28-2003 Berger, Y.  AJ4 US-6,638,211-B2 10-28-2003 Suslian et al.  AK4 US-6,644,525-B2 11-04-2003 Rocheleau et al.  AK4 US-6,668,921-B2 11-18-2003 Anderson et al.  AM4 US-6,685,629-B2 11-25-2003 Neisz et al.  AM4 US-6,685,629-B2 11-25-2003 Neisz et al.  AM4 US-6,685,629-B2 11-25-2003 Neisz et al.  AM4 US-6,685,629-B2 11-25-2004 Gellman  AP4 US-6,802,807 10-12-2004 Anderson et al.	7	AT3	US-6,423,080-B1	07-23-2002	Gellman et al.
AW3 US-6,491,703-B1 12-10-2002 Ulmsten, U.  AX3 US-6,494,887-B1 12-17-2002 Kaladelfos, G.  AY3 US-6,500,194-B2 12-31-2002 Benderev et al.  AZ3 US-6,502,578-B2 01-07-2003 Raz et al.  AA4 US-6,530,943-B1 03-11-2003 Hoepffner et al.  AB4 US-6,582,443 06-24-2003 Cabak et al.  AC4 US-6,596,001 07-22-2003 Stormby et al.  AD4 US-6,596,002 07-22-2003 Therin et al.  AE4 US-6,599,235 07-29-2003 Kovac  AF4 US-6,605,097-B1 08-12-2003 Lehe et al.  AG4 US-6,612,977-B1 09-02-2003 Staskin et al.  AH4 US-6,638,209-B2 10-28-2003 Landgrebe, S.  AI4 US-6,638,210-B2 10-28-2003 Berger, Y.  AJ4 US-6,638,211-B2 10-28-2003 Suslian et al.  AK4 US-6,641,525-B2 11-04-2003 Rocheleau et al.  AL4 US-6,648,921-B2 11-18-2003 Anderson et al.  AN4 US-6,652,450-B2 11-25-2003 Neisz et al.  AN4 US-6,658,629-B2 02-03-2004 Therin, M.  AO4 US-6,755,781 06-29-2004 Gellman  AP4 US-6,802,807 10-12-2004 Anderson et al.  AQ4 US-6,830,052 12-14-2004 Carter et al.		AU3	US-6,440,154-B2	08-27-2002	Gellman et al.
AX3 US-6,494,887-B1 12-17-2002 Kaladelfos, G.  AY3 US-6,500,194-B2 12-31-2002 Benderev et al.  AZ3 US-6,502,578-B2 01-07-2003 Raz et al.  AA4 US-6,530,943-B1 03-11-2003 Hoepffner et al.  AB4 US-6,582,443 06-24-2003 Cabak et al.  AC4 US-6,596,001 07-22-2003 Stormby et al.  AD4 US-6,596,002 07-22-2003 Therin et al.  AE4 US-6,599,235 07-29-2003 Kovac  AF4 US-6,605,097-B1 08-12-2003 Lehe et al.  AG4 US-6,612,977-B1 09-02-2003 Staskin et al.  AH4 US-6,638,209-B2 10-28-2003 Landgrebe, S.  AI4 US-6,638,210-B2 10-28-2003 Berger, Y.  AJ4 US-6,638,211-B2 10-28-2003 Suslian et al.  AK4 US-6,641,525-B2 11-04-2003 Rocheleau et al.  AL4 US-6,648,921-B2 11-18-2003 Anderson et al.  AM4 US-6,652,450-B2 11-25-2003 Neisz et al.  AM4 US-6,656,29-B2 02-03-2004 Therin, M.  AO4 US-6,755,781 06-29-2004 Gellman  AP4 US-6,802,807 10-12-2004 Anderson et al.  AQ4 US-6,830,052 12-14-2004 Carter et al.	17	AV3	US-6,478,727-B2	11-12-2002	Scetbon, V.
AY3 US-6,500,194-B2 12-31-2002 Benderev et al.  AZ3 US-6,502,578-B2 01-07-2003 Raz et al.  AA4 US-6,530,943-B1 03-11-2003 Hoepffner et al.  AB4 US-6,582,443 06-24-2003 Cabak et al.  AC4 US-6,596,001 07-22-2003 Stormby et al.  AD4 US-6,596,002 07-22-2003 Therin et al.  AE4 US-6,599,235 07-29-2003 Kovac  AF4 US-6,605,097-B1 08-12-2003 Lehe et al.  AG4 US-6,612,977-B1 09-02-2003 Staskin et al.  AH4 US-6,638,209-B2 10-28-2003 Landgrebe, S.  AI4 US-6,638,210-B2 10-28-2003 Berger, Y.  AJ4 US-6,638,211-B2 10-28-2003 Suslian et al.  AK4 US-6,641,525-B2 11-04-2003 Rocheleau et al.  AL4 US-6,685,629-B2 11-18-2003 Anderson et al.  AM4 US-6,685,629-B2 02-03-2004 Therin, M.  AO4 US-6,755,781 06-29-2004 Gellman  AP4 US-6,802,807 10-12-2004 Anderson et al.  AQ4 US-6,830,052 12-14-2004 Carter et al.	/	AW3	US-6,491,703-B1	12-10-2002	Ulmsten, U.
AZ3 US-6,502,578-B2 01-07-2003 Raz et al.  AA4 US-6,530,943-B1 03-11-2003 Hoepffner et al.  AB4 US-6,582,443 06-24-2003 Cabak et al.  AC4 US-6,596,001 07-22-2003 Stormby et al.  AD4 US-6,596,002 07-22-2003 Therin et al.  AE4 US-6,599,235 07-29-2003 Kovac  AF4 US-6,605,097-B1 08-12-2003 Lehe et al.  AG4 US-6,612,977-B1 09-02-2003 Staskin et al.  AH4 US-6,638,209-B2 10-28-2003 Landgrebe, S.  AI4 US-6,638,210-B2 10-28-2003 Berger, Y.  AJ4 US-6,638,211-B2 10-28-2003 Suslian et al.  AK4 US-6,641,525-B2 11-04-2003 Rocheleau et al.  AL4 US-6,644,921-B2 11-18-2003 Anderson et al.  AM4 US-6,652,450-B2 11-25-2003 Neisz et al.  AN4 US-6,652,450-B2 11-25-2003 Neisz et al.  AN4 US-6,685,629-B2 02-03-2004 Therin, M.  AO4 US-6,755,781 06-29-2004 Gellman  AP4 US-6,802,807 10-12-2004 Anderson et al.  AQ4 US-6,830,052 12-14-2004 Carter et al.	7	AX3	US-6,494,887-B1	12-17-2002	Kaladelfos, G.
AA4 US-6,530,943-B1 03-11-2003 Hoepffner et al.  AB4 US-6,582,443 06-24-2003 Cabak et al.  AC4 US-6,596,001 07-22-2003 Stormby et al.  AD4 US-6,596,002 07-22-2003 Therin et al.  AE4 US-6,599,235 07-29-2003 Kovac  AF4 US-6,605,097-B1 08-12-2003 Lehe et al.  AG4 US-6,612,977-B1 09-02-2003 Staskin et al.  AH4 US-6,638,209-B2 10-28-2003 Landgrebe, S.  AI4 US-6,638,210-B2 10-28-2003 Berger, Y.  AJ4 US-6,638,211-B2 10-28-2003 Suslian et al.  AK4 US-6,641,525-B2 11-04-2003 Rocheleau et al.  AL4 US-6,648,921-B2 11-18-2003 Anderson et al.  AM4 US-6,652,450-B2 11-25-2003 Neisz et al.  AN4 US-6,685,629-B2 02-03-2004 Therin, M.  AO4 US-6,755,781 06-29-2004 Gellman  AP4 US-6,802,807 10-12-2004 Anderson et al.  AQ4 US-6,830,052 12-14-2004 Carter et al.	7	AY3	US-6,500,194-B2	12-31-2002	Benderev et al.
AB4 US-6,582,443 06-24-2003 Cabak et al.  AC4 US-6,596,001 07-22-2003 Stormby et al.  AD4 US-6,596,002 07-22-2003 Therin et al.  AE4 US-6,599,235 07-29-2003 Kovac  AF4 US-6,605,097-B1 08-12-2003 Lehe et al.  AG4 US-6,612,977-B1 09-02-2003 Staskin et al.  AH4 US-6,638,209-B2 10-28-2003 Landgrebe, S.  AI4 US-6,638,210-B2 10-28-2003 Berger, Y.  AJ4 US-6,638,211-B2 10-28-2003 Suslian et al.  AK4 US-6,641,525-B2 11-04-2003 Rocheleau et al.  AK4 US-6,648,921-B2 11-18-2003 Anderson et al.  AM4 US-6,652,450-B2 11-25-2003 Neisz et al.  AN4 US-6,655,629-B2 02-03-2004 Therin, M.  AO4 US-6,755,781 06-29-2004 Gellman  AP4 US-6,802,807 10-12-2004 Anderson et al.  AQ4 US-6,830,052 12-14-2004 Carter et al.	7	AZ3	US-6,502,578-B2	01-07-2003	Raz et al.
AC4 US-6,596,001 07-22-2003 Stormby et al.  AD4 US-6,596,002 07-22-2003 Therin et al.  AE4 US-6,599,235 07-29-2003 Kovac  AF4 US-6,605,097-B1 08-12-2003 Lehe et al.  AG4 US-6,612,977-B1 09-02-2003 Staskin et al.  AH4 US-6,638,209-B2 10-28-2003 Landgrebe, S.  AI4 US-6,638,210-B2 10-28-2003 Berger, Y.  AJ4 US-6,638,211-B2 10-28-2003 Suslian et al.  AK4 US-6,641,525-B2 11-04-2003 Rocheleau et al.  AL4 US-6,648,921-B2 11-18-2003 Anderson et al.  AM4 US-6,652,450-B2 11-25-2003 Neisz et al.  AN4 US-6,685,629-B2 02-03-2004 Therin, M.  AO4 US-6,755,781 06-29-2004 Gellman  AP4 US-6,802,807 10-12-2004 Anderson et al.  AQ4 US-6,830,052 12-14-2004 Carter et al.	/	AA4	US-6,530,943-B1	03-11-2003	Hoepffner et al.
AD4 US-6,596,002 07-22-2003 Therin et al.  AE4 US-6,599,235 07-29-2003 Kovac  AF4 US-6,605,097-B1 08-12-2003 Lehe et al.  AG4 US-6,612,977-B1 09-02-2003 Staskin et al.  AH4 US-6,638,209-B2 10-28-2003 Landgrebe, S.  AI4 US-6,638,210-B2 10-28-2003 Berger, Y.  AJ4 US-6,638,211-B2 10-28-2003 Suslian et al.  AK4 US-6,641,525-B2 11-04-2003 Rocheleau et al.  AL4 US-6,648,921-B2 11-18-2003 Anderson et al.  AM4 US-6,652,450-B2 11-25-2003 Neisz et al.  AN4 US-6,685,629-B2 02-03-2004 Therin, M.  AO4 US-6,755,781 06-29-2004 Gellman  AP4 US-6,830,052 12-14-2004 Carter et al.	7	AB4	US-6,582,443	06-24-2003	Cabak et al.
AE4       US-6,599,235       07-29-2003       Kovac         AF4       US-6,605,097-B1       08-12-2003       Lehe et al.         AG4       US-6,612,977-B1       09-02-2003       Staskin et al.         AH4       US-6,638,209-B2       10-28-2003       Landgrebe, S.         AI4       US-6,638,210-B2       10-28-2003       Berger, Y.         AJ4       US-6,638,211-B2       10-28-2003       Suslian et al.         AK4       US-6,641,525-B2       11-04-2003       Rocheleau et al.         AL4       US-6,648,921-B2       11-18-2003       Anderson et al.         AM4       US-6,652,450-B2       11-25-2003       Neisz et al.         AN4       US-6,685,629-B2       02-03-2004       Therin, M.         AO4       US-6,755,781       06-29-2004       Gellman         AP4       US-6,830,052       12-14-2004       Carter et al.	/	AC4	US-6,596,001	07-22-2003	Stormby et al.
AF4 US-6,605,097-B1 08-12-2003 Lehe et al.  AG4 US-6,612,977-B1 09-02-2003 Staskin et al.  AH4 US-6,638,209-B2 10-28-2003 Landgrebe, S.  AI4 US-6,638,210-B2 10-28-2003 Berger, Y.  AJ4 US-6,638,211-B2 10-28-2003 Suslian et al.  AK4 US-6,641,525-B2 11-04-2003 Rocheleau et al.  AL4 US-6,648,921-B2 11-18-2003 Anderson et al.  AM4 US-6,652,450-B2 11-25-2003 Neisz et al.  AN4 US-6,685,629-B2 02-03-2004 Therin, M.  AO4 US-6,755,781 06-29-2004 Gellman  AP4 US-6,802,807 10-12-2004 Anderson et al.  AQ4 US-6,830,052 12-14-2004 Carter et al.	/	AD4	US-6,596,002	07-22-2003	Therin et al.
AG4 US-6,612,977-B1 09-02-2003 Staskin et al.  AH4 US-6,638,209-B2 10-28-2003 Landgrebe, S.  AI4 US-6,638,210-B2 10-28-2003 Berger, Y.  AJ4 US-6,638,211-B2 10-28-2003 Suslian et al.  AK4 US-6,641,525-B2 11-04-2003 Rocheleau et al.  AL4 US-6,648,921-B2 11-18-2003 Anderson et al.  AM4 US-6,652,450-B2 11-25-2003 Neisz et al.  AN4 US-6,685,629-B2 02-03-2004 Therin, M.  AO4 US-6,755,781 06-29-2004 Gellman  AP4 US-6,802,807 10-12-2004 Anderson et al.  AQ4 US-6,830,052 12-14-2004 Carter et al.	7	AE4	US-6,599,235	07-29-2003	Kovac
AH4 US-6,638,209-B2 10-28-2003 Landgrebe, S.  AI4 US-6,638,210-B2 10-28-2003 Berger, Y.  AJ4 US-6,638,211-B2 10-28-2003 Suslian et al.  AK4 US-6,641,525-B2 11-04-2003 Rocheleau et al.  AL4 US-6,648,921-B2 11-18-2003 Anderson et al.  AM4 US-6,652,450-B2 11-25-2003 Neisz et al.  AN4 US-6,685,629-B2 02-03-2004 Therin, M.  AO4 US-6,755,781 06-29-2004 Gellman  AP4 US-6,802,807 10-12-2004 Anderson et al.  AQ4 US-6,830,052 12-14-2004 Carter et al.	1	AF4	US-6,605,097-B1	08-12-2003	Lehe et al.
Al4 US-6,638,210-B2 10-28-2003 Berger, Y.  AJ4 US-6,638,211-B2 10-28-2003 Suslian et al.  AK4 US-6,641,525-B2 11-04-2003 Rocheleau et al.  AL4 US-6,648,921-B2 11-18-2003 Anderson et al.  AM4 US-6,652,450-B2 11-25-2003 Neisz et al.  AN4 US-6,685,629-B2 02-03-2004 Therin, M.  AO4 US-6,755,781 06-29-2004 Gellman  AP4 US-6,802,807 10-12-2004 Anderson et al.  AQ4 US-6,830,052 12-14-2004 Carter et al.	/	AG4	US-6,612,977-B1	09-02-2003	Staskin et al.
AJ4 US-6,638,211-B2 10-28-2003 Suslian et al.  AK4 US-6,641,525-B2 11-04-2003 Rocheleau et al.  AL4 US-6,648,921-B2 11-18-2003 Anderson et al.  AM4 US-6,652,450-B2 11-25-2003 Neisz et al.  AN4 US-6,685,629-B2 02-03-2004 Therin, M.  AO4 US-6,755,781 06-29-2004 Gellman  AP4 US-6,802,807 10-12-2004 Anderson et al.  AQ4 US-6,830,052 12-14-2004 Carter et al.	7	AH4	US-6,638,209-B2	10-28-2003	Landgrebe, S.
AK4       US-6,641,525-B2       11-04-2003       Rocheleau et al.         AL4       US-6,648,921-B2       11-18-2003       Anderson et al.         AM4       US-6,652,450-B2       11-25-2003       Neisz et al.         AN4       US-6,685,629-B2       02-03-2004       Therin, M.         AO4       US-6,755,781       06-29-2004       Gellman         AP4       US-6,802,807       10-12-2004       Anderson et al.         AQ4       US-6,830,052       12-14-2004       Carter et al.	1	AI4	US-6,638,210-B2		
AL4       US-6,648,921-B2       11-18-2003       Anderson et al.         AM4       US-6,652,450-B2       11-25-2003       Neisz et al.         AN4       US-6,685,629-B2       02-03-2004       Therin, M.         AO4       US-6,755,781       06-29-2004       Gellman         AP4       US-6,802,807       10-12-2004       Anderson et al.         AQ4       US-6,830,052       12-14-2004       Carter et al.	1	AJ4	US-6,638,211-B2	10-28-2003	Suslian et al.
AM4       US-6,652,450-B2       11-25-2003       Neisz et al.         AN4       US-6,685,629-B2       02-03-2004       Therin, M.         AO4       US-6,755,781       06-29-2004       Gellman         AP4       US-6,802,807       10-12-2004       Anderson et al.         AQ4       US-6,830,052       12-14-2004       Carter et al.	/	AK4	US-6,641,525-B2	11-04-2003	Rocheleau et al.
AN4 US-6,685,629-B2 02-03-2004 Therin, M.  AO4 US-6,755,781 06-29-2004 Gellman  AP4 US-6,802,807 10-12-2004 Anderson et al.  AQ4 US-6,830,052 12-14-2004 Carter et al.	1	AL4	US-6,648,921-B2	11-18-2003	Anderson et al.
AO4       US-6,755,781       06-29-2004       Gellman         AP4       US-6,802,807       10-12-2004       Anderson et al.         AQ4       US-6,830,052       12-14-2004       Carter et al.	,	AM4	US-6,652,450-B2	11-25-2003	Neisz et al.
AP4 US-6,802,807 10-12-2004 Anderson et al.  AQ4 US-6,830,052 12-14-2004 Carter et al.		AN4	US-6,685,629-B2	02-03-2004	Therin, M.
AQ4 US-6,830,052 12-14-2004 Carter et al.		AO4	US-6,755,781		Latina and the state of the sta
				10-12-2004	Anderson et al.
AR4 US-D466213 S 11-26-2002 Snitkin et al.				12-14-2004	Carter et al.
7.1.1.1 OOD 1002700 1.1.20 2002   0.1.1.1.1.1.0.1.0.1.		AR4	US-D466213 S	11-26-2002	Snitkin et al.

		FOREIG	GN PATENT	DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	
	BA	SU-1225547	04-23-1986	N.N. Kanshin et al.		Х
	BB	SU-1443873	12-15-1988	A. L. Kosakovskii		X
	ВС	WO-97/13465	04-17-1997	Ulmsten		
	BD	WO-98/34545	08-13-1998	Koh et al.		X
	BE	WO-02/32321	04-25-2002	Yeung et al.		
	BF	WO-05/007019	01-27-2005	Jamiolkowski et al.		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner	Date
Signature	Considered

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)	Complete if Known				
				Application Number	10/631364
INFORMATION DISCLOSURE				Filing Date	July 31, 2003
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	James Wagner
				Art Unit	3764
	(Use as many she	eets as	s necessary)	Examiner Name	Not Yet Assigned
Sheet	4	of	4	Attorney Docket Number	MIY-P01-032

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	Delorme, E. La bandelette trans-obturatice: un procede mini-invasif pour traiter l'incontinence urinarire d'effort de la femme. Progres en Urologie. 11:1306-13 (2001) (English translation provided)	X
	СВ	Giesy et al. Ureteral Instrumentation: A New System for Continued Access Via a Safety Guidewire. Journal of Urology. No. 4, Part 2, p. 282A (1988)	
	CC	Haab et al. Feasibility of Outpatient Percutaneous Bladder Neck Suspension Under Local Anesthesia. Urology. 50:4, 585-897 (1997)	
	CD	Jacquetin, B. Utilisation du TVT dans la chirurgie de l'incontinence urinaire feminine. J. Gynecol Obstet Biol Reprod. 29, 242-47 (2000)	X
	CE	Norris et al. Use of Synthetic Material in Sling Surgery: A Minimally Invasive Approach. Journal of Endourology. 10:3, 227-30 (1996)	
	CF	Petros, P. An Integral Theory of Bladder Neck Opening, Closure and Urinary Incontinence in the Female. International Journal of Gynecology & Obstetrics. XXIII World Congress of Gynaecology and Obstetrics (FIGO) 1991	
	CG	Petros, P. Medium-term Follow-up of the Intravaginal Slingplasty Operation Indicates Minimal Deterioration of Urinary Continence with Time. Aust NZ J Obstet Gynaecol. 39:3, 354-56 (1999)	
	CH	Raz et al. Vaginal Wall Sling. The Journal of Urology. 141:43-6 (1989)	
	CI	Raz et al. Fascial Sling to Correct Mail Neurogenic Sphincter Incompetence: The McGuire/Raz Approach." Journal of Urology. Vol. 139: 528-531 (1988)	
	CJ	Schostak et al., "Transvaginal bone anchors in femal stress urinary incontinence: Poor Results." Gynecologic and Obstetric Investigation, Vol. 54, no. 3, pps 154-158, 2002	
	CK	Staskin et al. The Gore-tex sling procedure for female sphincteric incontinence: indications, technique, and results. World J of Urol. 15:5, 295-99 (1997)	
	CL	Staskin, D.R. Sling Surgery for the Treatment of Female Stress Incontinence. 5:1, 106-22 (1991)	
	СМ	Sussman, et al. The Raz Bladder Neck Suspension: Five-Year Experience. The Journal of Urology. 145, 223A (1993)	
	CN	Ulmsten et al. A Multicenter Study of Tension-Free Vaginal Tape (TVT) for Surgical Treatment of Stress Urinary Incontinence. Int Urogynecol J. 9:4, 210-13 (1998)	
	СО	Ulmsten et al. Surgery for female urinary incontinence. Current Opinion in Obstetrics & Gynecology. 4:3, 456-62 (1992)	
	CP	Ulmsten et al. Connective Tissue Factors in the Aetiology of Female Pelvic Disorders. Ann. Med. 22:6, 3 (1990)	
	CQ	Ulmsten, U. An Introduction to Tension-Free Vaginal Tape (TVT) - A New Surgical Procedure for Treatment of Female Urinary Incontinence. Int Urogynecol J. (Suppl 2): S3-4 (2001)	
	CR	Ulmsten, U. The basic understanding and clinical results of tension-free vaginal tape for stress urinary incontinence. Der Urologe [A] 40:269-73 (2001)	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner	Date
Signature	Considered